U.S. markets closed

Grifols, S.A. (GRF.MC)

MCE - MCE Delayed Price. Currency in EUR
Add to watchlist
15.38-0.34 (-2.16%)
At close: 05:35PM CET

Grifols, S.A.

Avinguda de la Generalitat, 152
Parc empresarial Can Sant Joan Sant Cugat del VallEs
Barcelona 08174
34 93 571 00 00

IndustryDrug Manufacturers—General
Full Time Employees23,431

Key Executives

NameTitlePayExercisedYear Born
Mr. Raimon Grifols RouraCo-CEO & Exec. Director1.17MN/A1964
Mr. Víctor Grífols DeuCo-CEO & Exec. Director1.17MN/A1977
Mr. Alfredo Arroyo GuerraCFO & VPN/AN/A1958
Mrs. Eva Bastida TubauCorp. VP and Director of Scientific & Medical AffairsN/AN/AN/A
Ms. Nuria Pascual LapeñaVP of Corp. Treasury & Investor RelationsN/AN/A1964
Mr. David Ian BellGen. Counsel & Chief Corp. Devel. OfficerN/AN/A1955
Ms. Maria Teresa-Rioné LlanoVP of Corp. CommunicationsN/AN/A1966
Mr. Mateo Florencio Borrás HumbertCorp. VP & Chief HR OfficerN/AN/A1956
Mr. Francisco Javier Jorba RibesCorp. VP and Pres of the Biological Industrial GroupN/AN/A1951
Mrs. Montserrat Lloveras CalvoCorp. VP and Director of Corp. Accounting & ReportingN/AN/A1962
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others segments. The Bioscience segment produces plasma-derived medicines for the treatment of rare, chronic, and life-threatening conditions. It offers intravenous immunoglobin, albumin, alpha-1-antitrypsin, factor VIII, antithrombin, and other specialty hyperimmune immunoglobulins. The Hospital segment offers non-biological pharmaceutical products and medical supplies for hospital pharmacy, such as intravenous solutions, pharmatech solutions, clinical nutrition products, and medical devices for interventional therapy. The Diagnostic segment manufactures and markets diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides engineering services; and rents industrial buildings. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Corporate Governance

Grifols, S.A.’s ISS Governance QualityScore as of September 26, 2021 is 3. The pillar scores are Audit: 4; Board: 3; Shareholder Rights: 9; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.